… wherein the one or more additional agents is selected from the group consisting of aducanumab, solanezumab, CSP-1103, Mannitol, Osmitrol, Resectisol, Phenytoin, Dilantin, Phenytek, valproic acid, Depakote, Gabapentin, Neurontin, Topiramate, Topamax, Carbamazepine, Equetro, anti-platelet medications …
